Thomas Januario
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Monoclonal and Polyclonal Antibodies Research, Hedgehog Signaling Pathway Studies, Genomics and Chromatin Dynamics, Click Chemistry and Applications
Most-Cited Works
- → Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib(2005)1,482 cited
- → A paracrine requirement for hedgehog signalling in cancer(2008)954 cited
- → Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma(2009)841 cited
- → Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL(2007)602 cited
- → Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients(2005)490 cited
- → Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma(2015)384 cited
- → Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance(2010)363 cited
- → TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer(2011)312 cited
- → Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer(2009)187 cited
- → Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients(2020)147 cited